Huiyu Pharmaceutical(SH:688553) Ge Long Hui·2025-08-04 08:15Core Viewpoint - Huiyu Pharmaceutical (688553.SH) announced that its wholly-owned subsidiary, Sichuan Huiyu Haiyue Pharmaceutical Technology Co., Ltd., has initiated a Phase I clinical trial for its self-developed innovative biological drug, HY05350, aimed at treating advanced solid tumors [1] Group 1 - The drug HY05350 has received approval from the National Medical Products Administration for clinical trials and is undergoing a multi-center, open-label Phase I/II clinical study [1] - The primary objective of the study is to evaluate the safety and tolerability of HY05350 in patients with MSLN-positive advanced solid tumors during the dose escalation phase [1] - The study will explore the maximum tolerated dose (MTD) and provide recommended doses (RP2D) for subsequent clinical research [1]